BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.
| Revenue (Most Recent Fiscal Year) | $3.25B |
| Net Income (Most Recent Fiscal Year) | $-1.29B |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.01 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.05 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 67.82 |
| Pre-Tax Margin (Trailing 12 Months) | -42.39% |
| Net Margin (Trailing 12 Months) | -44.39% |
| Return on Equity (Trailing 12 Months) | -5.30% |
| Return on Assets (Trailing 12 Months) | -4.62% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.80 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.74 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | 3.74 |
| Book Value per Share (Most Recent Fiscal Quarter) | $96.59 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.54 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.88 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 252.88M |
| Free Float | 204.33M |
| Market Capitalization | $22.90B |
| Average Volume (Last 20 Days) | 1.05M |
| Beta (Past 60 Months) | 1.32 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.52% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |